Moderna reports Q3 EPS (51c), consensus ($2.18)

Reports Q3 revenue $1.02B, consensus $869.89M. “We delivered strong commercial and financial performance in the third quarter, supported by COVID vaccine sales following the successful launch of mNEXSPIKE and a significant improvement in expected 2025 operating expenses from our ongoing cost-reduction initiatives,” said Stephane Bancel, CEO of Moderna (MRNA). “We remain highly focused on operational excellence and financial discipline to advance our pipeline and expand the reach of our commercial portfolio. We look forward to sharing further updates on our business and pipeline at our annual Analyst Day on November 20.”